JP7022066B2 - 代謝機能不全によって引き起こされる腫瘍の治療 - Google Patents

代謝機能不全によって引き起こされる腫瘍の治療 Download PDF

Info

Publication number
JP7022066B2
JP7022066B2 JP2018536151A JP2018536151A JP7022066B2 JP 7022066 B2 JP7022066 B2 JP 7022066B2 JP 2018536151 A JP2018536151 A JP 2018536151A JP 2018536151 A JP2018536151 A JP 2018536151A JP 7022066 B2 JP7022066 B2 JP 7022066B2
Authority
JP
Japan
Prior art keywords
cancer
compound
present disclosure
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501206A (ja
JP2019501206A5 (enExample
Inventor
シャナハン ジェイムズ
コーネリアス ピーター
Original Assignee
シンデブルックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンデブルックス，インコーポレイティド filed Critical シンデブルックス，インコーポレイティド
Publication of JP2019501206A publication Critical patent/JP2019501206A/ja
Publication of JP2019501206A5 publication Critical patent/JP2019501206A5/ja
Priority to JP2022016251A priority Critical patent/JP7640481B2/ja
Application granted granted Critical
Publication of JP7022066B2 publication Critical patent/JP7022066B2/ja
Priority to JP2025025705A priority patent/JP2025071236A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018536151A 2016-01-11 2017-01-11 代謝機能不全によって引き起こされる腫瘍の治療 Active JP7022066B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022016251A JP7640481B2 (ja) 2016-01-11 2022-02-04 代謝機能不全によって引き起こされる腫瘍の治療
JP2025025705A JP2025071236A (ja) 2016-01-11 2025-02-20 代謝機能不全によって引き起こされる腫瘍の治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662277293P 2016-01-11 2016-01-11
US62/277,293 2016-01-11
US201662393929P 2016-09-13 2016-09-13
US62/393,929 2016-09-13
US201662395446P 2016-09-16 2016-09-16
US62/395,446 2016-09-16
PCT/US2017/012968 WO2017123603A1 (en) 2016-01-11 2017-01-11 Treatment for tumors driven by metabolic dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022016251A Division JP7640481B2 (ja) 2016-01-11 2022-02-04 代謝機能不全によって引き起こされる腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2019501206A JP2019501206A (ja) 2019-01-17
JP2019501206A5 JP2019501206A5 (enExample) 2020-02-20
JP7022066B2 true JP7022066B2 (ja) 2022-02-17

Family

ID=57882196

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018536151A Active JP7022066B2 (ja) 2016-01-11 2017-01-11 代謝機能不全によって引き起こされる腫瘍の治療
JP2022016251A Active JP7640481B2 (ja) 2016-01-11 2022-02-04 代謝機能不全によって引き起こされる腫瘍の治療
JP2025025705A Pending JP2025071236A (ja) 2016-01-11 2025-02-20 代謝機能不全によって引き起こされる腫瘍の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022016251A Active JP7640481B2 (ja) 2016-01-11 2022-02-04 代謝機能不全によって引き起こされる腫瘍の治療
JP2025025705A Pending JP2025071236A (ja) 2016-01-11 2025-02-20 代謝機能不全によって引き起こされる腫瘍の治療

Country Status (9)

Country Link
US (3) US10646463B2 (enExample)
EP (1) EP3402529A1 (enExample)
JP (3) JP7022066B2 (enExample)
KR (2) KR20260036617A (enExample)
CN (2) CN114225045B (enExample)
AU (3) AU2017206718B2 (enExample)
CA (2) CA3239447A1 (enExample)
MX (2) MX2018008321A (enExample)
WO (1) WO2017123603A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2853204T3 (es) * 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
MX386958B (es) 2013-04-10 2025-03-19 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y métodos de tratamiento de la obesidad.
AU2016366306B2 (en) 2015-12-10 2021-02-25 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
CN107670048B (zh) 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
CN113453721B (zh) * 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
CN112915210B (zh) * 2019-12-06 2024-08-20 重庆阿普格雷生物科技有限公司 一种聚乙二醇偶联药物、其制备方法及应用
MX2023005501A (es) * 2020-11-11 2023-07-27 Syndevrx Inc Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
CN116887836A (zh) * 2020-11-11 2023-10-13 辛德弗雷克斯公司 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
JP2025526665A (ja) * 2022-08-10 2025-08-15 シンデブルックス，インコーポレイティド 肺線維症の治療のためのｍｅｔａｐ２阻害剤
KR20250117799A (ko) * 2022-11-16 2025-08-05 신데브알엑스, 인크. 전립선암의 치료를 위한 metap2 억제제
CN119932197B (zh) * 2025-04-09 2025-06-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150088A1 (en) 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates
WO2014169026A1 (en) 2013-04-10 2014-10-16 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
AU3352799A (en) 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
BR9910092A (pt) 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
HK1040052B (zh) 1998-05-22 2006-09-15 第一制药株式会社 药物复合物
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
EP1619210A1 (en) 1998-10-30 2006-01-25 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
US6803438B1 (en) 1999-09-08 2004-10-12 Polytherics Limited Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1436286B1 (en) 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
EP1483579A4 (en) 2002-02-15 2006-07-12 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
EP1494662B1 (en) 2002-04-11 2012-11-28 Children's Medical Center Corporation Tnp-470-hpma-methacrylic acid copolymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
US7700280B2 (en) * 2003-12-31 2010-04-20 The Penn State Research Foundation Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
CN101990441A (zh) 2007-11-28 2011-03-23 默萨那治疗学股份有限公司 生物相容的生物可降解的烟曲霉素类似物轭合物
CN101896177A (zh) * 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CN102105156B (zh) 2008-05-22 2016-05-25 特拉维夫大学拉莫特有限公司 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
TWI373345B (en) 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
AU2011204267B2 (en) * 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
PH12013500934A1 (en) * 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
DK2786753T3 (en) * 2010-11-12 2019-04-15 Pharma Mar Sa Combination therapy with an antitumor antibiotic
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
SI3033086T1 (sl) * 2013-08-14 2022-01-31 Novartis Ag Kombinirana terapija za zdravljenje raka
AU2016366306B2 (en) 2015-12-10 2021-02-25 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
WO2018027084A2 (en) 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150088A1 (en) 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates
WO2014169026A1 (en) 2013-04-10 2014-10-16 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy，2014年，Vol.7，p.73-84
レジデント，2015年，Vol.8、No.9，p.6-7

Also Published As

Publication number Publication date
US11273142B2 (en) 2022-03-15
JP2022048388A (ja) 2022-03-25
KR20260036617A (ko) 2026-03-17
CN114225045B (zh) 2025-09-26
KR102934569B1 (ko) 2026-03-04
JP2019501206A (ja) 2019-01-17
CN108697807A (zh) 2018-10-23
AU2021286420B2 (en) 2024-03-14
MX2018008321A (es) 2018-09-21
US20170196830A1 (en) 2017-07-13
AU2024204027A1 (en) 2024-07-04
WO2017123603A1 (en) 2017-07-20
AU2017206718B2 (en) 2021-09-30
CA3008960A1 (en) 2017-07-20
CA3239447A1 (en) 2017-07-20
CN114225045A (zh) 2022-03-25
US20210077452A1 (en) 2021-03-18
CA3008960C (en) 2024-07-02
MX2023002076A (es) 2023-03-17
JP7640481B2 (ja) 2025-03-05
AU2021286420A1 (en) 2022-01-20
AU2017206718A1 (en) 2018-07-05
KR20180100663A (ko) 2018-09-11
CN108697807B (zh) 2021-11-26
EP3402529A1 (en) 2018-11-21
JP2025071236A (ja) 2025-05-02
US20220280470A1 (en) 2022-09-08
US10646463B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
JP2022048388A (ja) 代謝機能不全によって引き起こされる腫瘍の治療
US12419846B2 (en) Biomarkers of METAP2 inhibitors and applications thereof
TW202038951A (zh) 用於治療癌症之醫藥組合
HUE029036T2 (en) FGF receptor (FGFR) agonist dimer compounds, methods for their preparation and their therapeutic use
CN111132690A (zh) 胰高血糖素和glp-1受体的长效共激动剂
KR102346033B1 (ko) 단백질 타이로신 키나아제 조절인자로서의 ｎ-(3-플루오로벤질)-2-(5-(4-모르폴리노페닐)피리딘-2-일)아세트아미드
TWI324066B (en) A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor
TW201010732A (en) Method of treating RAS associated cancer
TW202116356A (zh) 作為治療劑之微管靶向藥劑之肽結合物
JP2024531374A (ja) タキソールコンジュゲート化合物、これを含む医薬組成物およびそれらを使用する方法
TW201221126A (en) Methods for treatment of non-small cell lung cancer

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220204

R150 Certificate of patent or registration of utility model

Ref document number: 7022066

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250